MeiraGTx

MeiraGTx MGTX Stock

$8.32   -1.654850%
Add to favorites
Market Cap
$813.12M
LOW - HIGH [24H]
$8.30 - $8.64
VOLUME [24H]
$584.57K
P/E Ratio
9.56
Earnings per share
$0.87
ISIN
KYG596651029
Price   Prediction

MeiraGTx Price Chart

Sorry, that's all we've gotfor now...

MeiraGTx (MGTX) stock price today is 8.32 USD on Tech Market Large (-1.65% on the day). Updated .

MeiraGTx MGTX Financial and Trading Overview

MeiraGTx stock price 8.32 USD
Previous Close 8.46 USD
Open 8.4 USD
Bid 6.21 USD x 200
Ask 10.88 USD x 200
Day's Range 8.39 - 8.64 USD
52 Week Range 6.62 - 15.35 USD
Volume 40.85K USD
Avg. Volume 837.73K USD
Market Cap 838.04M USD
Beta (5Y Monthly) 1.071
PE Ratio (TTM) 9.856321
EPS (TTM) 0.87 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 27.75 USD

MGTX Valuation Measures

Enterprise Value 776.14M USD
Trailing P/E 9.856321
Forward P/E -5.704004
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 2.085168
Price/Book (mrq) 3.8924193
Enterprise Value/Revenue 1.931
Enterprise Value/EBITDA 4.042

Trading Information

MeiraGTx Stock Price History

Beta (5Y Monthly) 1.071
52-Week Change 11.60%
S&P500 52-Week Change 10.51%
52 Week High 15.35 USD
52 Week Low 6.62 USD
50-Day Moving Average 10.51 USD
200-Day Moving Average 10.39 USD

MGTX Share Statistics

Avg. Volume (3 month) 837.73K USD
Avg. Daily Volume (10-Days) 738.94K USD
Shares Outstanding 97.73M
Float 55.52M
Short Ratio 7.93
% Held by Insiders 15.99%
% Held by Institutions 73.32%
Shares Short 6.64M
Short % of Float 9.42%
Short % of Shares Outstanding 6.80%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 19.47%
Operating Margin (ttm) 44.83%
Gross Margin 97.19%
EBITDA Margin 47.77%

Management Effectiveness

Return on Assets (ttm) 37.46%
Return on Equity (ttm) 89.50%

Income Statement

Revenue (ttm) 401.9M USD
Revenue Per Share (ttm) 4.58 USD
Quarterly Revenue Growth (yoy) 1074.09%
Gross Profit (ttm) 390.64M USD
EBITDA 192M USD
Net Income Avi to Common (ttm) 78.28M USD
Diluted EPS (ttm) 0.87
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 184.65M USD
Total Cash Per Share (mrq) 1.89 USD
Total Debt (mrq) 133.85M USD
Total Debt/Equity (mrq) 62.19 USD
Current Ratio (mrq) 4.625
Book Value Per Share (mrq) 2.203

Cash Flow Statement

Operating Cash Flow (ttm) 1.36M USD
Levered Free Cash Flow (ttm) 47.4M USD

Profile of MeiraGTx

Country United States
State NY
City New York
Address 655 Third Avenue
ZIP 10017
Phone 646 860 7985
Website https://www.meiragtx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 386

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Q&A For MeiraGTx Stock

What is a current MGTX stock price?

MeiraGTx MGTX stock price today per share is 8.32 USD.

How to purchase MeiraGTx stock?

You can buy MGTX shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for MeiraGTx?

The stock symbol or ticker of MeiraGTx is MGTX.

Which industry does the MeiraGTx company belong to?

The MeiraGTx industry is Biotechnology.

How many shares does MeiraGTx have in circulation?

The max supply of MeiraGTx shares is 97.73M.

What is MeiraGTx Price to Earnings Ratio (PE Ratio)?

MeiraGTx PE Ratio is 9.56321800 now.

What was MeiraGTx earnings per share over the trailing 12 months (TTM)?

MeiraGTx EPS is 0.87 USD over the trailing 12 months.

Which sector does the MeiraGTx company belong to?

The MeiraGTx sector is Healthcare.

MeiraGTx MGTX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24429.89 USD —
+0.42
7.16B USD — 24225.3 USD — 24538.78 USD — — 7.16B USD —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Global Select Market Com NQGS US 12034.87 USD —
+0.42
— — 11933.12 USD — 12087.81 USD — — — —
us US Tech Biotechnology NBI US 6971.7 USD —
-0.66
— — 6959.96 USD — 7076.43 USD — — — —
us US Tech Health Care IXHC US 1324.44 USD —
-0.63
— — 1322.85 USD — 1342.46 USD — — — —
$2.19T
Total marketcap
$73.52B
Total volume
BTC 58.09%   •   ETH 10.01%
Dominance
Select currency